RALES (see Randomized Aldactone Evaluation Study (RALES))
Raloxifene, 2277t
adverse effects of, 2281
for breast cancer, 2048
contraindications, 2281
dosing, 2280–2281
for osteoporosis, 2271
Raltegravir (RAL), 1581t
Ramelteon (Rozerem), 1768
for sleep, 1861
for treatment of insomnia, 1767t, 1768
Ramipril, 281–282, 281t, 609
in hypertension, 153t
Ramucirumab, 469t
for colon cancer, 2073, 2078
Randomized Aldactone Evaluation Study (RALES), 270
Ranibizumab, 1169
Ranitidine, 977, 1216t, 2163t
H2RA, 483t, 484
for preventing SRMB, 515t
RANKL inhibitors, 2096
Ranolazine, 120t, 211
for chronic stable angina, 214–215, 224, 224t
for myocardial ischemia, 223
Rapivab (see Peramivir)
Rasagiline, 1251t, 1255–1256, 1264
Rasburicase, 918
for AML, 2027
R-CHOP, 2042
Recombivax-HB, 1355
Rectal diazepam gel, 1294
Red clover, 942t
Reglan (see Metoclopramide)
Regorafenib, 470t
for colon cancer, 2073
Relaxation, 1024
Relenza (see Zanamivir)
Renagel (see Sevelamer)
RenAmin, 794t
Renvela (see Sevelamer)
Repaglinide, 1116, 1141
adverse effects of, 1113
contraindications and precautions of, 1113
dosage and clinical use of, 1117
drug interactions of, 1116
efficacy, 1116–1117
mechanism of action, 1113
pharmacokinetics of, 1113
Replens, 1037
Requip (see Ropinirole)
Reserpine, 157t
for hypertension, 159–160
Resorcinol, 1626
Restoril (see Temazepam)
Reteplase, 237
Retinoids, 827, 828
Revlimid (see Lenalidomide)
Rexulti (see Brexpiprazole)
Rhinocort Aqua (see Budesonide)
Rho
(D) immune globulin (RhoGAM), 999
Ribavirin (Virazole), 1649t
administration of, 1658
adverse effects, 1647t, 1658
for HCV, 1686
for HPS, 1659
for liver transplant recipients, 1686
for RSV, 1657–1658
for SARS, 1660
use in infants, 1657
for WNV infection, 1659–1660
Riboflavin, 173
Rifabutin
for MAC, 1619
for TB, 1616, 1617t
for tuberculosis, 1429t
Rifamate, 1429
Rifampin, 42, 53, 120t, 662, 942, 1370, 1376, 1720
acute renal failure and, 1437
adverse reactions with, 1437
and AIN, 645
for CNS infections, 1373t
discoloration of body fluids and, 1437
dosing of, 1338t
drug interactions with, 1437
flulike syndrome and, 1436–1437
for HAV, 1688
and hepatotoxicity, 1437
isoniazid and, 1437
for MAC, 1619
thrombocytopenia and, 1437
for tuberculosis, 1429t, 1433
Rifamycin, 942t, 1616
Rifapentine, 1429t
Rifater, 1429
Rifaximin (Xifaxan)
for global IBS symptoms, 536
hepatic encephalopathy, 553
for IBS with diarrhea, 536
and neomycin, 553
SBP and, 1474
for travelers’ diarrhea, 1461t
Rilonacept, 903
Rilpivirine (RPV), 1578t
Rimantadine (Flumadine), 1649t
adverse effects, 1647t
for influenza, 1655–1656
pharmacokinetics of, 1653t
Risedronate, 2277, 2277t, 2278
Risperdal (see Risperidone)
Risperidone (Risperdal), 1267, 1739, 1796t, 1797t, 1799t
fo
r
a
c
ut
e
ma
nia
,
1
8
4
5
t
fo
r
a
g
it
a
t
e
d
b
e
h
a
v
io
r
s
,
2
2
4
4
fo
r
A
S
D
,
1
8
5
6
,
1
8
6
0
fo
r
B
D
,
1
9
9
7
t
fo
r
b
ip
o
la
r
dis
o
r
d
e
r
,
1
8
4
9
t
fo
r
d
e
v
e
lop
me
nt
a
l
dis
o
r
d
e
r
s
,
1
8
5
7
fo
r
dy
s
lip
id
e
mia
,
1
8
0
3
fo
r
F
GA
s
,
1
8
0
3
fo
r
hyp
e
rp
r
o
la
c
t
in
e
mia
,
1
8
0
3
fo
r
O
C
D
,
1
7
5
7
fo
r
o
r
th
o
s
t
a
t
ic
hyp
o
t
e
n
s
io
n
,
1
8
0
1
fo
r
s
c
h
iz
op
hr
e
nia
,
1
7
8
8
,
1
7
9
0
,
1
7
9
2
,
1
7
9
2
t
,
1
7
9
3
,
1
7
9
3
t
R
i
t
o
n
av
i
r
(
R
T
V)
,
1
2
0
t
,
1
2
8
,
9
4
2
t
,
1
5
7
9
t
fo
r
S
A
R
S
,
1
6
6
0
R
i
t
u
x
a
n
(
s
e
e
R
i
t
u
x
i
m
a
b
)
R
i
t
u
x
i
m
a
b
,
4
6
9
t
,
6
4
1
,
8
8
1
,
8
8
3
,
8
9
6
t
,
8
9
7
,
8
9
8
–
8
9
9
,
1
9
8
2
t
,
2
0
4
0
t
fo
r
a
g
gr
e
s
s
iv
e
lymp
h
o
ma
s
,
2
0
4
2
fo
r
C
L
L
,
2
0
3
4
th
e
r
a
p
y
fo
r
LN
,
6
2
6
R
i
v
a
r
o
x
a
b
a
n
,
1
3
0
7
t
fo
r
mo
n
o
th
e
r
a
p
y
,
1
8
7
fo
r
p
r
e
v
e
nt
io
n
o
f
s
tr
o
ke
,
3
1
7
–
3
1
8
fo
r
s
tr
o
ke
p
r
e
v
e
nt
io
n
,
1
7
8
fo
r
w
a
r
fa
r
in
th
e
r
a
p
y
,
2
0
0
R
i
v
a
s
t
i
g
m
i
n
e
,
1
2
6
7
fo
r
A
lzh
e
ime
r
’
s
dis
e
a
s
e
,
2
2
3
8
fo
r
v
a
s
c
ula
r
d
e
me
nt
ia
,
2
2
4
2
R
i
z
a
t
ri
p
t
a
n
,
1
2
3
8
t
,
1
2
3
9
R
o
b
e
p
r
az
o
l
e
,
1
2
1
6
t
R
o
c
e
p
h
i
n
(
s
e
e
C
e
ft
ri
a
x
o
n
e
)
R
o
c
u
r
o
n
i
u
m
,
2
2
0
0
t
R
o
fe
c
o
x
i
b
,
5
0
0
,
7
0
7
R
o
fl
u
m
i
l
a
s
t
,
6
1
0
R
o
l
a
p
i
t
a
n
t
(
Va
r
u
b
i
)
,
4
7
2
t
No comments:
Post a Comment
اكتب تعليق حول الموضوع